Bicycle Therapeutics (BCYC) Liabilities and Shareholders Equity: 2018-2025
Historic Liabilities and Shareholders Equity for Bicycle Therapeutics (BCYC) over the last 7 years, with Sep 2025 value amounting to $764.0 million.
- Bicycle Therapeutics' Liabilities and Shareholders Equity fell 23.36% to $764.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 billion, marking a year-over-year increase of 7.52%. This contributed to the annual value of $956.9 million for FY2024, which is 60.73% up from last year.
- Per Bicycle Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $764.0 million for Q3 2025, which was down 8.20% from $832.2 million recorded in Q2 2025.
- In the past 5 years, Bicycle Therapeutics' Liabilities and Shareholders Equity registered a high of $1.1 billion during Q2 2024, and its lowest value of $223.8 million during Q1 2021.
- For the 3-year period, Bicycle Therapeutics' Liabilities and Shareholders Equity averaged around $741.4 million, with its median value being $764.0 million (2025).
- As far as peak fluctuations go, Bicycle Therapeutics' Liabilities and Shareholders Equity skyrocketed by 197.73% in 2021, and later declined by 23.36% in 2025.
- Quarterly analysis of 5 years shows Bicycle Therapeutics' Liabilities and Shareholders Equity stood at $479.8 million in 2021, then fell by 14.42% to $410.6 million in 2022, then skyrocketed by 44.99% to $595.3 million in 2023, then soared by 60.73% to $956.9 million in 2024, then fell by 23.36% to $764.0 million in 2025.
- Its last three reported values are $764.0 million in Q3 2025, $832.2 million for Q2 2025, and $883.9 million during Q1 2025.